David Villafuerte Martinez, MD
Pulmonary Disease · Michigan City, INNPI 1336520576
Payments from drug & device makers
What this record shows
This record is dominated by education: $9,213 of the $11,105 with a category attached, or 83.0%. Intuitive Surgical accounts for 81.4% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $9,595 and has fallen 97.5% since, to $235 in 2025.
Across 94 payments — averaging $118.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$9K
- GSK$267
- Regeneron Healthcare Solutions, Inc.$257
- Boehringer Ingelheim$250
- Insmed, Inc.$209
- AstraZeneca$159
- plus $924 from 18 others
What the payments were for
- Food & beverage$1,89217%
- Education$9,21383%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $9,039 |
| GSK | 18 | $267 |
| Regeneron Healthcare Solutions, Inc. | 7 | $257 |
| Boehringer Ingelheim | 10 | $250 |
| Insmed, Inc. | 11 | $209 |
| AstraZeneca | 10 | $159 |
| Novartis | 6 | $105 |
| Genentech USA, Inc. | 1 | $100 |
| Pulmonx Corporation | 1 | $89 |
| Actelion Pharmaceuticals US, Inc. | 3 | $76 |
| Johnson & Johnson | 2 | $75 |
| Mallinckrodt Hospital Products Inc. | 2 | $67 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Amgen | 3 | $54 |
| Mylan Specialty L.p. | 3 | $46 |
| Paratek Pharmaceuticals, Inc. | 2 | $45 |
| Sanofi | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Inogen, Inc. | 1 | $26 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $26 |
| Grifols USA, LLC | 1 | $23 |
| Verona Pharma, Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Harmony Biosciences LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,000
- ION$3,000
How this compares
$11,105 in reported general payments places this provider in the 80th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 302 | $239,393 |
| Dupixent PenDupilumab | 30 | $113,105 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 123 | $88,555 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $30,860 |
| Spiriva RespimatTiotropium Bromide | 45 | $25,214 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 41 | $24,008 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $22,217 |
| EliquisApixaban | 18 | $10,657 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $10,409 |
| Arnuity ElliptaFluticasone Furoate | 25 | $7,374 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,878 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,560 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 208 | $4,675 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $3,404 |
| Wixela InhubFluticasone Propion/Salmeterol | 26 | $1,959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $267 | $306,722446 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $159 | $94,115140 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $250 | $59,631103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Michigan City
- Brian DickoverMichigan City$12K
- Albert NaveedMichigan City$9K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.